Attention-Deficit-Hyperactivity Disorder – Current Treatment – Current Treatment: Physician Insights – Pediatric ADHD (US)
Attention-deficit/hyperactivity disorder (ADHD) is a common childhood condition that can continue through adolescence and into adulthood. Treatment options include a mix of stimulants (e.g., methylphenidates, amphetamines) and nonstimulants (e.g., dopaminergic/noradrenergic agents, adrenergic receptor agonists). Despite many available—and largely efficacious—pharmacological treatments, a large proportion of patients have inadequate control of their ADHD symptoms, including over the long term. Overall, treatment is highly individualized and complex; thus, understanding drivers of treatment decision-making is key for current players in this market to help optimize uptake of their agents and for new players entering this large yet generic market.
QUESTIONS ANSWERED
- What factors help U.S. physicians determine if a pediatric ADHD patient is fit for prescription drug treatment? What are the drivers and constraints influencing physicians’ treatment decisions for pediatric ADHD? How are nonpharmacological approaches used?
- How long does it take for patients to progress between lines of therapy? How are patients being treated across different lines of therapy?
- To what extent is polypharmacy prescribed for pediatric ADHD, and what are physicians’ preferred drug combinations?
- How has use of key therapies changed in the past year, and what changes do physicians expect in their prescribing of these drugs in one year?
- How do Daytrana (Noven), Mydayis (Shire), and Vyvanse (Shire) compete in the generics-heavy pediatric ADHDtherapy market? What drivers and constraints will aid or restrict their use?
PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 50 U.S. PCPs/pediatricians and 50 U.S. psychiatrists fielded in January 2019
Key companies: Eli Lilly, Ironshore Pharmaceuticals, Janssen, Neos Therapeutics, Novartis, Noven Pharmaceuticals, Rhodes Pharmaceutical, Shire, Teva
Key drugs: Adderall IR/XR, Aptensio XR, Concerta, Cotempla XRODT, Daytrana, Jornay PM, Mydayis, Ritalin SR/LA, Strattera, Vyvanse
